Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: May 28, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit every 2 weeks, and 5 to 10 days of radiation therapy

PHASE: I

NCT ID: NCT03524170

Immunotherapy and Radiation Therapy for Metastatic ER+, HER2-Breast Cancer

RACHEL1: A Phase I Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Scientific Title

Purpose
To determine the best dose, safety and effects (good and bad) of M7824 combined with radiation therapy.
Who is this for?
People with estrogen receptor positive and HER2 negative metastatic (stage IV) breast cancer. You must have at least two sites of metastatic disease by imaging.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">M7824, by IV, every 2 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Radiation therapy, daily, 5-10 days</li> <li class="seamTextUnorderedListItem">Biopsy after 2 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">M7824 (MSB0011359C) is a protein with two components: PD-L1 antibody and TGF-β receptor. </li> <li class="seamTextUnorderedListItem">M7824 is currently being used for research purposes only.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03524170' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://stm.sciencemag.org/content/10/424/eaan5488' target='_blank'>Science Translational Medicine: M7824</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/publications/oncolog/radiation-may-enhance-immunotherapy-for-solid-tumors.h10-1591413.html' target='_blank'>MD Anderson Cancer Center: Radiation May Enhance Immunotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976948/' target='_blank'>Journal Article: Evolution of Radiation Therapy in MBC</a> </li></ul>
See more